Validation of the Turkish Version of the Modified Early Obstetric Warning Systems (MEOWS) Charts

December 22, 2022 updated by: Hale Kefeli Celik, Samsun Education and Research Hospital
It was aimed to study MEOWS on patients in the obstetrics clinic and to evaluate the performance of this scale as a screening tool and to contribute to its usability in Turkey by translating MEOWS into Turkish.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The Modified Early Obstetric Warning System (MEOWS) is a score-based or color-coded system used to detect changes in physiological parameters and enable earlier recognition and management of deteriorating patients.It was first validated by Sigh et al., then its validity and reliability were demonstrated in many countries, especially in countries with low socio-economic status.Early warning systems are not routinely used in obstetrics clinics in Turkey, and there is no Turkish version of MEOWS in the literature. In this study, it was aimed to study MEOWS on patients in obstetrics clinics and to evaluate the performance of this scale as a screening tool and to validate MEOWS by translating it into Turkish.

The study was carried out in 3 stages. The first stage is the translation of MEOWS into Turkish and its cultural adaptation, the second stage is the use of the study scale and the elimination of deficiencies by conducting a pilot study on 30 patients, and the third stage is the collection and evaluation of patient data until the specified sample size is reached.

Study Type

Observational

Enrollment (Actual)

350

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Samsun, Turkey, 55090
        • Samsun Research and Education Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Patients whose pregnancy is older than 28 weeks and between 6 weeks postpartum

Description

Inclusion Criteria:

  • Obstetric patients receiving inpatient treatment in obstetrics and gynecology clinics
  • Patients whose pregnancy is older than 28 weeks and between 6 weeks postpartum
  • Patients who agreed to participate in the study

Exclusion Criteria:

  • Patients who did not agree to participate in the study
  • Patients under the age of 18
  • Outpatients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pregnant and postpartum patients
Pregnant patients older than 28th gestational week and patients up to postpartum 6th week who were hospitalized in the obstetrics department
Other: patient-administered questionnaires
patient-administered questionnaires (MEOWS): Obstetric early warning systems are recommended to provide timely recognition, treatment and early referral of critically ill or developing patients. The development of early warning systems from simple bedside observation charts arose from the knowledge that physiological disturbances precede critical illness. Thanks to these charts, the fact that the patient's findings are in the risky value ranges allows the clinician to evaluate the patient earlier and in detail. MEOWS is a simple screening tool for maternal morbidity.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Validation of the Modified Early Obstetric Warning System
Time Frame: Obstetric patients older than 28 weeks of gestation and between 6 weeks postpartum
Demonstrating the reliability and validity of the Modified Early Obstetric Warning System chart in Turkish. MEOWS chart is contained within a booklet and is commenced on admission to hospital. The same booklet is used during subsequent admissions to hospital during the relevant pregnant and postnatal period. Specific maternal observations that are recorded on the MEOWS chart are diastolic blood pressure, severity of pain, antenatal discharge and/or postnatal lochia and proteinurea. Physiological parameters which deviate from the norm are allocated a score. The score increases as deviation from the norm escalates. The final score then falls into one of three categories: a low, medium, or high score. A low score is 1-4, a medium score is 5-6 and a high score is 7 or more. Any single score of 3 indicates an extreme variation from the normal, which is considered at least a medium score. The colour prompts are green for a low score, amber for medium and red for high scores.
Obstetric patients older than 28 weeks of gestation and between 6 weeks postpartum
Modified Early Obstetric Warning System Chart
Time Frame: At the end of the study, assessed up to 1 month.
Calculation of sensitivity, specificity, positive and negative predictive value of the chart
At the end of the study, assessed up to 1 month.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Samsun Education and Research Hospital

Investigators

  • Study Director: HALE KEFELI CELIK, MD, Samsun Research and Education Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2022

Primary Completion (Actual)

October 1, 2022

Study Completion (Actual)

November 1, 2022

Study Registration Dates

First Submitted

December 14, 2022

First Submitted That Met QC Criteria

December 22, 2022

First Posted (Estimate)

January 10, 2023

Study Record Updates

Last Update Posted (Estimate)

January 10, 2023

Last Update Submitted That Met QC Criteria

December 22, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • MEOWS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

Our data and statistical analysis of each investigated all parameter and data are available after the publication of the clinical study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Validation

Clinical Trials on patient-administered questionnaires

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe